BiotechTube

Bortezomib + Rituximab + Rituximab

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin's Lymphoma

Conditions

Non-Hodgkin's Lymphoma

Trial Timeline

Mar 1, 2006 → Jul 1, 2010

NCT ID
NCT00312845

About Bortezomib + Rituximab + Rituximab

Bortezomib + Rituximab + Rituximab is a phase 3 stage product being developed by Johnson & Johnson for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00312845. Target conditions include Non-Hodgkin's Lymphoma.

What happened to similar drugs?

7 of 20 similar drugs in Non-Hodgkin's Lymphoma were approved

Approved (7) Terminated (3) Active (10)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved
✅rituximabBiogenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00312845Phase 3Completed

Competing Products

20 competing products in Non-Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + Rituximab + BendamustineAbbViePhase 1
29
ABBV-291AbbViePhase 1
36
ABT-199AbbViePhase 1
29
AvelumabMerckPhase 1
33
Pembrolizumab + Flt3L + Poly ICLCMerckPhase 1/2
28